# Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events

> **NCT00346242** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (—)

## Conditions studied

- Thalassemia

## Interventions

- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT00346242
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2012-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346242, "Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00346242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*